Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, has announced interim results from its investigator-initiated Phase 2 Proof of Concept (PoC) study of VT-1953 topical gel, which is being tested in patients with malignant fungating wounds (MFW). The interim results were first presented at the annual meeting of the American Association for Cancer Research. The study showed that VT-1953 significantly reduced the primary endpoint of malignant fungating wound-associated malodor, with statistical significance (P<0.001). Additionally, patients reported significant improvements in secondary endpoints, including lesion pain and quality of life, both with statistical significance (P<0.001). Vyome Co-founder Dr. Shiladitya Sengupta will further discuss these preliminary results and the MFW market in a live video conference scheduled for Monday, September 8, 2025. Full study results are anticipated in October 2026, and Vyome plans to engage with the FDA in early 2026.